

Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases (e.g. Avise[®] CTD)

Policy MP-025

Origination Date: 02/28/2024

Reviewed/Revised Date: 02/28/2024

Next Review Date: 02/28/2025

Current Effective Date: 04/28/2024

Disclaimer:

1. Policies are subject to change in accordance with State and Federal notice requirements.
2. Policies outline coverage determinations for U of U Health Plans Commercial, CHIP and Healthy U (Medicaid) plans. Refer to the "Policy" section for more information.
3. Services requiring prior-authorization may not be covered, if prior-authorization is not obtained.
4. **This Medical Policy does not guarantee coverage or payment of the service. The service must be a benefit in the member's plan and the member must be eligible for coverage at the time of service. Additional payment guidelines may be applied that are not included in this policy.**

Description:

Connective tissue holds the body together as it surrounds and supports other tissues and organs. Tendons, ligaments, skin, blood vessels, and cartilage are examples of connective tissue. Connective tissue is also found in many organs such as the heart and lungs. Connective tissue is made up of two main proteins, elastin and collagen. If the connective tissue becomes inflamed, the inflammation can damage the elastin and collagen and it can affect the body parts they are associated with. There are many different connective tissue diseases (CTDs), and their symptoms can overlap. Tests that look at several different substances in the blood at one time have been developed to try to identify specific CTDs. These tests are unproven. More studies are needed to see if they bring more health benefits than the standard ways of diagnosing these disorders.

Systemic lupus erythematosus (SLE) is an autoimmune CTD that can be difficult to diagnose because individuals often present with diverse, nonspecific symptoms that overlap with other CTDs. The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus. About 90% of lupus patients are women of child bearing age, between the ages of 15 and 44 years. SLE causes inflammation and can affect any part of the body, most commonly the skin, heart, joints, lungs, blood vessels, liver, kidneys, and nervous system.

Currently, the differential diagnosis for SLE depends on a combination of clinical signs and symptoms and individual laboratory tests, which are not highly accurate. Also, similar symptoms may present themselves in individuals with fibromyalgia. More accurate laboratory tests for SLE and other CTDs could facilitate diagnosis of the disease. Laboratory-developed, diagnostic panel tests with proprietary algorithms and/or index scores for the diagnosis of SLE and other autoimmune CTDs have become commercially available.

Policy Statement and Criteria

1. Commercial Plans/CHIP

U of U Health Plans does NOT cover serum biomarker panel testing with proprietary algorithms and/or index scores for the diagnosis of systemic lupus erythematosus and other connective tissue diseases as current published evidence is insufficient to determine efficacy of this testing. They are considered investigational.

The following tests are considered investigational and therefore not covered (may not be an all-inclusive list):

- Avise[®] CTD
- Avise[®] Lupus
- Avise[®] SLE Monitor
- Avise[®] SLE Prognostic
- SLE-key[®] Rule Out, Veracis, Inc.

2. Medicaid Plans

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the U of U Health Plans Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website at: <https://medicaid.utah.gov/utah-medicaid-official-publications/> or the [Utah Medicaid code Look-Up tool](#)

CPT/HCPCS codes covered by Utah State Medicaid may still require further evaluation to determine medical necessity for coverage.

Clinical Rationale

A 2020 cohort study (Liang, et. al.) evaluated the utility of the AVISE[®] CTD test in predicting SLE disease development and damage progression. Patients who had undergone AVISE CTD testing were assessed for SLE diagnosis by the Systemic Lupus International Collaborating Clinics (SLICC) and American College of Rheumatology (ACR) criteria and for SLE damage by the SLICC Damage Index (SDI) at the time of AVISE testing (t=0) and 2 years later (t=2). Among 117 patients without a previous diagnosis of SLE, 65% of patients who tested positive developed SLE at t=2, compared with 10.3% of patients who tested non-

positive ($p < 0.0001$). AVISE-positive patients fulfilled significantly more SLICC diagnostic criteria than AVISE-non-positive patients at both $t=0$ (3.8 ± 2.1 vs 1.9 ± 1.1 , $p=0.001$) and $t=2$ (4.5 ± 2.2 vs 2.1 ± 1.2 , $p < 0.0001$). AVISE-positive patients also had significantly higher SDI at $t=2$ (1.9 ± 1.3 vs 1.03 ± 1.3 , $p=0.01$). BC4d levels correlated with the number of SLICC criteria at $t=0$ ($r=0.33$, $p < 0.0001$) and $t=2$ ($r=0.34$, $p < 0.0001$), as well as SDI at $t=0$ ($r=0.25$, $p=0.003$) and $t=2$ ($r=0.26$, $p=0.002$). The study found that the AVISE CTD test can aid in SLE evaluation by predicting SLE disease development and future damage progression. However, further more robust comparative studies are needed, with longer term follow-up, to evaluate the utility of AVISE in predicting longitudinal disease activity and flares.

No guidelines or statements were identified.

A search of [ClinicalTrials.gov](https://clinicaltrials.gov) in February 2024 did not identify any ongoing or unpublished trials that would likely influence this review.

Applicable Coding

CPT Codes

- 0062U** Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score
- 0312U** Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment
- 81599** Unlisted multianalyte assay with algorithmic analysis
- 84999** Unlisted chemistry procedure

HCPCS Codes

Not applicable

References:

1. American College of Rheumatology (ACR). 1997 Update of the 1982 American College of Rheumatology Revised Criteria for Classification of Systemic Lupus Erythematosus. n.d. Accessed July 13, 2023. <https://www.rheumatology.org/Portals/0/Files/1997%20Update%20of%201982%20Revised.pdf>.
2. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol*. Sep 2019; 71(9): 1400-1412. PMID 31385462
3. Bae SC, Koh HK, Chang DK, et al. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. *Lupus*. 2001; 10(6): 405-9. PMID 11434575
4. Food and Drug Administration. Guidance for Industry: Systemic Lupus Erythematosus - Developing Medical Products for Treatment. June 2010. <https://www.fda.gov/media/71150/download>. Accessed July 13, 2023.
5. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum*. Mar 1996; 39(3): 363-9. PMID 8607884
6. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. *J Rheumatol*. Feb 2002; 29(2): 288-91. PMID 11838846
7. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. *Arthritis Rheum*. Sep 1999; 42(9): 1785-96. PMID 10513791
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. Sep 1997; 40(9): 1725. PMID 9324032

9. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. *Rheumatology (Oxford)*. Jul 2005; 44(7): 902-6. PMID 15814577
10. J C-V, Chitkara P, Christianakis S, et al. Finding the best approach to autoimmune connective tissue disease diagnosis (Paid supplement supported by Exagen Diagnostics). *Rheumatology News*. 2014; August:1-8.
11. Kalunian KC, Chatham WW, Massarotti EM, et al. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. *Arthritis Rheum*. Dec 2012; 64(12): 4040-7. PMID 22932861
12. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. *Medicine (Baltimore)*. May 2006; 85(3): 147-156. PMID 16721257
13. Liang E, Taylor M, McMahon M. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression. *Lupus Sci Med*. 2020; 7(1): e000345. PMID 32231785
14. Liang, E., M. Taylor and M. McMahon (2020). "Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression." *Lupus Sci Med* 7(1): e000345.
15. Liu CC, Kao AH, Hawkins DM, et al. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. *Clin Transl Sci*. Aug 2009; 2(4): 300-8. PMID 20161444
16. McElhone K, Abbott J, Shelmerdine J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. *Arthritis Rheum*. Aug 15 2007; 57(6): 972-9. PMID 17665467
17. Mossell J, Goldman JA, Barken D, et al. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. *Open Rheumatol J*. 2016; 10: 71-80. PMID 27867431
18. National Library of Medicine. ClinicalTrials.gov. Accessed: February 14, 2024. Available at: <https://www.clinicaltrials.gov/>
19. National Resource Center on Lupus. Lupus Foundation of America. "Lupus facts and statistics". Accessed February 13, 2024. Available at: <https://www.lupus.org/resources/lupus-facts-and-statistics>
20. Navratil JS, Manzi S, Kao AH, et al. Platelet C4d is highly specific for systemic lupus erythematosus. *Arthritis Rheum*. Feb 2006; 54(2): 670-4. PMID 16447243
21. O'Malley T, Xie F, Su Y, et al. Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus. *J Manag Care Spec Pharm*. Sep 2022; 28(9): 1021-1032. PMID 35775579
22. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum*. Aug 2012; 64(8): 2677-86. PMID 22553077
23. Putterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. *Lupus Sci Med*. 2014; 1(1): e000056. PMID 25396070
24. Ramsey-Goldman R, Alexander RV, Conklin J, et al. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. *ACR Open Rheumatol*. Feb 2021; 3(2): 116-123. PMID 33538130
25. Ramsey-Goldman R, Alexander RV, Massarotti EM, et al. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. *Arthritis Rheumatol*. Jan 2020; 72(1): 78-88. PMID 31469249
26. Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). *Arthritis Care Res (Hoboken)*. Nov 2011; 63 Suppl 11(0 11): S37-46. PMID 22588757
27. Suresh E. Systemic lupus erythematosus: diagnosis for the non-specialist. *Br J Hosp Med (Lond)*. Oct 2007; 68(10): 538-41. PMID 17974296
28. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. *Clin Exp Rheumatol*. 1992; 10(5): 541-7. PMID 1458710
29. Wallace DJ, Alexander RV, O'Malley T, et al. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. *Lupus Sci Med*. 2019; 6(1): e000349. PMID 31592328
30. Wallace DJ, Silverman SL, Conklin J, et al. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. *Lupus Sci Med*. 2016; 3(1): e000127. PMID 26870391

Disclaimer:

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

U of U Health Plans makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. U of U Health Plans updates its Coverage Policies regularly, and reserves the right to amend these policies and give notice in accordance with State and Federal requirements.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from U of U Health Plans.

"University of Utah Health Plans" and its accompanying logo, and its accompanying marks are protected and registered trademarks of the provider of this Service and or University of Utah Health. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association